Potential public health and economic impact of the next-generation COVID-19 vaccine mRNA-1283 in the Netherlands

A modeling study in the Netherlands demonstrates that the next-generation mRNA-1283 vaccine is projected to significantly reduce COVID-19 infections, hospitalizations, and deaths while offering substantial health and economic benefits over existing vaccines, supporting its continued use in national vaccination programs.

The Gist

Imagine the Netherlands is a large, bustling city that has been under constant siege by a sneaky, shape-shifting invader called SARS-CoV-2 (the virus that causes COVID-19). Even though the worst of the initial storm has passed, the invader is still lurking in the shadows, ready to cause trouble every winter.

This paper is like a strategic war room simulation run by health experts to answer a big question: "If we upgrade our city's defense system with a new, super-charged shield (the mRNA-1283 vaccine), is it worth the extra cost compared to the old shields we've been using?"

Here is the breakdown of their findings using everyday analogies:

1. The Problem: The "Leaky Roof"

Without any new vaccines, the experts predicted that over the next two winter seasons, the "roof" of the city would leak badly.

• The Leak: About 460,000 people would catch the virus.
• The Damage: This would lead to 23,800 people needing to be hospitalized (like emergency room triage) and 5,300 tragic deaths.
• The Cost: The city would spend a fortune just fixing the damage (medical bills).

2. The New Shield: mRNA-1283

The city has a new type of shield called mRNA-1283. Think of the old shields (mRNA-1273 and BNT162b2) as standard umbrellas. They are good, but the new shield is like an umbrella made of high-tech, self-repairing material that blocks the rain even better, especially when the storm gets fierce.

The study looked at two groups of people:

• The Elderly (60+): The most vulnerable residents.
• The High-Risk Workers (18-59): People with health conditions who are like the city's essential firefighters and doctors.

3. The Results: Plugging the Holes

When they ran the simulation with the new shield, the results were impressive:

• Fewer Leaks: They prevented 68,000 infections. That's like keeping 68,000 people from getting sick in the first place.
• Fewer Emergencies: They saved 5,400 hospital beds. Imagine 5,400 empty beds in the hospital that don't need to be filled because people stayed healthy.
• Lives Saved: They prevented 1,200 deaths.
• Money Saved: By keeping people out of the hospital, the city saved over €66.5 million in medical bills.

4. The Price Tag: Is It Worth It?

Now, the tricky part: How much should the city pay for this new shield?

The experts used a "Willingness-to-Pay" meter set at €50,000 for every year of healthy life saved (a standard rule of thumb in health economics).

• Versus Doing Nothing: If the city buys the new vaccine instead of doing nothing, they can justify paying up to €238 per person for it.
• Versus the Old Shields: This is the real kicker. The new shield is better than the old ones.
  • Compared to the previous best vaccine (mRNA-1273), the new one prevents an extra 1,309 hospitalizations. The extra cost to get this "upgrade" is only about €62 per person.
  • Compared to the other common vaccine (BNT162b2), it prevents an extra 1,679 hospitalizations. The extra cost is only about €80 per person.

The Bottom Line

Think of it like buying a car. You could buy a basic model that gets you from A to B. But this new vaccine is like buying a luxury model with better safety features and a longer warranty.

The study concludes that even though the new vaccine costs a little more than the old ones, the "safety features" (preventing hospitalizations and deaths) are so good that the extra few dozen euros per person is a steal. It's a smart investment that keeps the city healthier and saves the economy money in the long run.

In short: The new vaccine is a powerful, cost-effective upgrade that acts like a heavy-duty raincoat, keeping the Netherlands drier, safer, and wealthier than if they stuck with the old gear.

Technical Summary

1. Problem Statement

Despite the availability of originally licensed COVID-19 vaccines, SARS-CoV-2 remains a significant public health challenge in the Netherlands. The emergence of next-generation vaccines, specifically mRNA-1283 (approved in the EU), offers the potential for higher relative efficacy compared to earlier vaccines (mRNA-1273 and BNT162b2). However, there was a lack of quantitative data regarding the specific public health and economic value of adopting mRNA-1283 within the Dutch healthcare system. The study aimed to model the impact of mRNA-1283 versus a "no vaccination" scenario and versus existing vaccines to determine its cost-effectiveness and justify pricing strategies.

2. Methodology

The researchers employed a static Markov model with a 1-year time horizon, adapted from previously published literature. The study focused on two specific target populations:

• Adults aged 60 years and older.
• High-risk individuals aged 18–59 years.

Key Modeling Parameters:

• Comparators: The model compared mRNA-1283 against:
  1. No vaccination.
  2. Originally licensed mRNA-1273 (Moderna).
  3. Originally licensed BNT162b2 (Pfizer-BioNTech).
• Timeframe: The model simulated two full post-pandemic seasons to reflect the ongoing burden of COVID-19.
• Efficacy Data:
  • Efficacy of mRNA-1283 vs. mRNA-1273 was derived from pivotal Phase 3 NextCOVE trial data.
  • Efficacy vs. BNT162b2 was calculated using an indirect treatment comparison (ITC).
• Economic Thresholds: Cost-effectiveness was evaluated using a Willingness-to-Pay (WTP) threshold of €50,000 per Quality-Adjusted Life Year (QALY) gained.
• Key Metrics: The study calculated the Economically Justifiable Price (EJP) and price premiums required to make the vaccine cost-effective.

3. Key Contributions

• First Economic Evaluation in the Netherlands: This study provides the first comprehensive health economic analysis specifically tailored to the Dutch context for the next-generation mRNA-1283 vaccine.
• Comparative Analysis: Unlike studies that only compare new vaccines to "no vaccination," this paper explicitly benchmarks mRNA-1283 against currently used vaccines (mRNA-1273 and BNT162b2), offering insights into incremental benefits.
• Pricing Framework: It establishes specific price points (EJP) that would render the vaccine cost-effective, providing a data-driven basis for negotiations between health authorities and manufacturers.

4. Results

The model projected significant health and economic outcomes under different scenarios:

Baseline Burden (Without Vaccination):

• Estimated 460,000 infections.
• 23,800 hospitalizations.
• 5,300 deaths.

Impact of mRNA-1283 (with current coverage):

• Prevented 68,000 infections, 5,400 hospitalizations, and 1,200 deaths.
• Generated 9,667 QALYs.
• Saved over €66.5 million in direct treatment costs.

Cost-Effectiveness and Pricing:

• Versus No Vaccination: The EJP for mRNA-1283 was calculated at €238 per dose.
• Versus mRNA-1273: mRNA-1283 prevented an additional 1,309 hospitalizations. It was deemed cost-effective at an incremental price premium of €62 over mRNA-1273.
• Versus BNT162b2: mRNA-1283 prevented an additional 1,679 hospitalizations. It was cost-effective at an incremental price premium of €80 over BNT162b2.

5. Significance

The study concludes that continued vaccination is essential to mitigate the ongoing societal and health burden of SARS-CoV-2 in the Netherlands. Specifically, the adoption of mRNA-1283 is projected to offer substantial health benefits over originally licensed mRNA vaccines.

From an economic perspective, the results suggest that even with a higher price point, mRNA-1283 represents a cost-effective intervention that improves health outcomes and economic efficiency within the national vaccination program. The findings support policy decisions to include mRNA-1283 in the Dutch vaccination strategy, highlighting its potential to reduce hospitalizations and mortality more effectively than previous vaccine generations.